Nicotine decreases bradykinesia-rigidity in haloperidol-treated patients with schizophrenia.
We applied nicotine 21 mg and matching placebo transdermal patches to thirty haloperidol-treated patients with schizophrenia who smoked. Clinical assessments of bradykinesia-rigidity were lower during nicotine patch administration than during placebo patch administration.
Yang
Yen Kuang
YK
National Cheng Kung University, Taiwan, China.
Nelson
Leann
L
Kamaraju
Lakshmi
L
Wilson
William
W
McEvoy
Joseph P
JP
D000279:Administration, Cutaneous; D000328:Adult; D018726:Anti-Dyskinesia Agents / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D005260:Female; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D018476:Hypokinesia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009127:Muscle Rigidity / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D009538:Nicotine / Q000008:administration & dosage* / Q000009:adverse effects; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D012907:Smoking / Q000378:metabolism
D018726:Anti-Dyskinesia Agents; D009538:Nicotine; D006220:Haloperidol